Bernd Schweikert
Overview
Explore the profile of Bernd Schweikert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
378
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferry T, Gogos C, Soriano A, Blasi F, Ansari W, Kantecki M, et al.
Infect Drug Resist
. 2024 Jul;
17:2773-2783.
PMID: 38979062
Background: Ceftaroline fosamil is approved for the treatment of complicated skin and soft tissue infections (cSSTI) and community-acquired pneumonia (CAP); however, data on its real-world use and effectiveness in Europe...
2.
Soriano A, Bassetti M, Gogos C, Ferry T, de Pablo R, Ansari W, et al.
JAC Antimicrob Resist
. 2024 May;
6(3):dlae078.
PMID: 38803385
Background: This multicentre, observational, retrospective chart review study assessed ceftaroline fosamil treatment patterns and outcomes in adults hospitalized with community-acquired pneumonia (CAP) in usual care settings. Methods: Anonymized patient data...
3.
Waser N, Quintana M, Schweikert B, Chaft J, Berry L, Adam A, et al.
JNCI Cancer Spectr
. 2024 Mar;
8(3).
PMID: 38521542
Background: Surrogate endpoints for overall survival in patients with resectable non-small cell lung cancer receiving neoadjuvant therapy are needed to provide earlier treatment outcome indicators and accelerate drug approval. This...
4.
Yee K, Alexanderian D, Feng Y, Ren X, Schweikert B, Ayodele O
J Health Econ Outcomes Res
. 2022 Sep;
9(2):67-76.
PMID: 36168594
Mucopolysaccharidosis II (MPS II; Hunter syndrome; OMIM 309900) is a rare, X-linked, lysosomal storage disease caused by deficient iduronate-2-sulfatase activity. Accumulation of glycosaminoglycans results in multisystemic disease manifestations, which may...
5.
Jin H, Liu Y, Schweikert B, Hahman H, Wang L, Imhof A, et al.
Cardiol Res Pract
. 2022 Feb;
2022:6538296.
PMID: 35111341
Background: Acute coronary syndrome (ACS) causes pathophysiological changes in exercise capacity, N-terminal part of pro-brain natriuretic peptide (NT-proBNP), and adiponectin that impact the course of coronary artery disease and clinical...
6.
Hadji P, Schweikert B, Kloppmann E, Gille P, Joeres L, Toth E, et al.
Arch Gynecol Obstet
. 2021 Jul;
304(3):703-712.
PMID: 34247254
Purpose: In osteoporosis, prior fracture is a strong predictor of subsequent fracture. This study aimed to assess the imminent risk of subsequent fracture following an initial fracture in osteoporosis patients...
7.
Schweikert B, Malmberg C, Nunez M, Dilla T, Sapin C, Hartz S
BMJ Open
. 2020 Aug;
10(8):e032552.
PMID: 32792421
Objective: To conduct a cost-effectiveness analysis from the perspective of the Spanish National Health System (NHS) comparing ixekizumab versus secukinumab. Design: A Markov model with a lifetime horizon and monthly...
8.
Schweikert B, Malmberg C, Akerborg O, Kumar G, Nott D, Kiri S, et al.
Pharmacoecon Open
. 2020 Mar;
4(4):635-648.
PMID: 32166657
Background: Interleukin-17A (IL-17A) antagonists are a recent innovation for treating psoriatic arthritis (PsA). There are currently no cost-effectiveness analyses (CEAs) comparing the IL-17A antagonists ixekizumab and secukinumab in PsA from...
9.
Leidl R, Schweikert B, Hahmann H, Steinacker J, Reitmeir P
Health Qual Life Outcomes
. 2016 Mar;
14:48.
PMID: 27005466
Background: Quality of life as an endpoint in a clinical study may be sensitive to the value set used to derive a single score. Focusing on patients' actual valuations in...
10.
Schweikert B, Pittrow D, Vizza C, Pepke-Zaba J, Hoeper M, Gabriel A, et al.
BMC Health Serv Res
. 2014 Jun;
14:246.
PMID: 24912804
Background: Chronic Thromboembolic Pulmonary Hypertension (CTEPH) results from incomplete resolution of a pulmonary embolus, leading to pulmonary hypertension and progressive right heart failure and death. We aimed to describe the...